Metformin XR plus placebo + Metformin XR plus liraglutide
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gestational Diabetes Mellitus
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Trial Timeline
Aug 11, 2011 → Jun 14, 2019
NCT ID
NCT01234649About Metformin XR plus placebo + Metformin XR plus liraglutide
Metformin XR plus placebo + Metformin XR plus liraglutide is a phase 3 stage product being developed by Novo Nordisk for Gestational Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01234649. Target conditions include Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01234649 | Phase 3 | Completed |
Competing Products
18 competing products in Gestational Diabetes Mellitus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin | Eli Lilly | Phase 3 | 77 |
| Insulin LISPRO + Insulin, Long-Acting and Insulin | Eli Lilly | Approved | 85 |
| Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| Avelumab Injection + Methotrexate 1 GM Injection | Merck | Phase 1/2 | 41 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| Metformin + placebo | Novo Nordisk | Approved | 84 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Liraglutide + Placebo | Novo Nordisk | Approved | 84 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| growth hormone | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Omnitrope | Sandoz Group | Approved | 82 |
| Inhaled Technosphere Insulin | MannKind Corp | Phase 2/3 | 60 |